WARSAW, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host educational and networking events at IPOS and its continued support of the event as an Emerald-Level sponsor. IPOS, a branch of the Pediatric Orthopedic Society of North America (POSNA), is a leading educational meeting for pediatric orthopedic surgeons. Over 500 pediatric orthopedic surgeons are registered to attend the meeting from December 3-7, in Orlando, Florida.
“This year marks the 20th Annual IPOS meeting, and I couldn’t be prouder of our partnership with this surgical society, and our participation in this meeting,” said David Bailey, President and CEO of OrthoPediatrics. “IPOS is a great educational opportunity for early career surgeons, and our team is excited to connect with customers and share hands-on learning experiences with our new and innovative products. I’m especially excited to introduce our new Enabling Technology division as well as highlight all the great work we are doing in non-operative care through OPSB Specialty Bracing.”
In addition to the exhibition booths (#1 - 3), wherein the Company will highlight their full suite of products, and feature its new Enabling Technology division with 7D, 3-D Side and the new Specialty Bracing division (OPSB), the Company is hosting several educational experiences for surgeons and other allied health professionals. OrthoPediatrics IPOS 2024 Events include:
Pre-course
Industry Spotlight Sessions
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 70 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
Last Trade: | US$22.33 |
Daily Change: | -0.13 -0.58 |
Daily Volume: | 256,348 |
Market Cap: | US$540.830M |
November 26, 2024 November 06, 2024 August 05, 2024 August 05, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB